GET DAILY SIGNALSAxon (AXON) Analyst Targets Average $650, Pointing to +53% Upside
Key Takeaways
- The central target is $650, the arithmetic mean of nine recent, attributed analyst price targets, with a wide range of roughly $470 to $800.
- At a recent price near $425.87, reaching $650 would require a gain of about 53%—a very large move.
- For context, broader aggregator consensus (roughly $680–$690) sits near or slightly above the calculated mean, reflecting similar but not identical coverage.
- Key supports include roughly 30%-plus revenue growth, AI and drone expansion, and federal counter-drone (UAS) orders.
- Principal risks are order and bookings volatility, software (SaaS) and margin concerns, and a rich valuation with a trailing P/E near 176.
- The analyst range is unusually wide because bulls emphasize a large, underpenetrated market while cautious voices flag slowing orders and multiple compression.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages.
- To see how AI screens the broader market, explore Trending AI Robots.
Breaking Down the Analyst Price Targets
AXON is Axon Enterprise, Inc., a Nasdaq-listed maker of conducted energy weapons (TASER) and body-worn cameras, plus an expanding software, sensors, drone, and AI platform for public safety. Nine recent, individually attributed price targets were reviewed, spanning roughly $470 to $800. Their average is about $649, rounded to a $650 central target. At the top, Goldman Sachs (Michael Ng) and TD Cowen (Andrew Sherman) hold $800 Buy ratings. Raymond James (Brian Gesuale) and Morgan Stanley (Meta Marshall) sit at $675 with Outperform/Overweight ratings, while RBC Capital is at $735. In the middle, Needham (Joshua Reilly) is at $600, Piper Sandler (James Fish) at $561, and Barclays (Tim Long) at $523. The most cautious is UBS (Andrew Spinola) at $470 with a Neutral rating. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Notably, recent changes have been target cuts rather than rating downgrades. Piper Sandler lowered its target from $732 to $561 in October 2026, Raymond James from $800 to $675, UBS from $600 to $470, and TD Cowen from $825 to $800. Earlier in 2026, Barclays cut to $523, Needham to $600, and Morgan Stanley to $675. This pattern reflects a resetting of multiples across growth software rather than a collapse in the fundamental thesis.
Current Market Position and Path Toward the Target
AXON closed near $425.87 on October 27, 2026, toward the lower end of a 52-week range of roughly $339 to $764. The stock has fallen about 43% over the past year amid SaaS, M&A, and margin concerns. Reaching $650 from $425.87 implies roughly 53% upside—a very large move that would require both operational re-acceleration and multiple expansion. The path would likely run through improved quarterly bookings, evidence that software and services margins are stabilizing, and continued traction in AI-enabled products and counter-UAS demand. Because the shares trade at a trailing P/E near 176, sentiment and valuation, not just results, would need to recover.
What Could Support a Move Toward the Target
AXON has sustained roughly 30%-plus revenue growth, with management guiding to continued expansion across TASER, sensors, and software. Analysts point to a large, underpenetrated total addressable market, sticky public-safety customers, cross-selling into new verticals such as retail and healthcare, and new products including the Axon Body Workforce Mini. Federal counter-UAS orders and higher-margin AI software, along with acquisitions of Carbyne and Prepared to modernize 911 operations, are cited as growth drivers. A stronger fourth quarter and clearer FY26 guidance could support a re-rating.
What Could Prevent the Target From Being Reached
The primary obstacle is execution risk. Recent quarters showed disappointing orders and bookings, with timing-related weakness in software and services. Valuation compression is a real threat for a stock trading near 176 times trailing earnings, particularly if interest rates stay elevated or growth software multiples reset further. Government budget cycles, regulation, and intensifying competition could also pressure growth. If bookings remain soft or margins fail to expand, the premium multiple may not recover even with solid revenue growth.
Technical Levels and Market Structure
AXON trades well below its 52-week high near $764, leaving meaningful overhead supply. The $500 level is a key psychological hurdle, followed by resistance in the $560–$600 zone where several lowered targets cluster. On the downside, the $400 area has provided recent support, with the 52-week low near $339 as a more durable floor. Reaching $650 would require clearing the $500 and $600 zones decisively—levels that align with the cautious end of the analyst range.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual timelines vary. The next major catalyst is Axon's third-quarter 2026 earnings report, scheduled around November 5, 2026, followed by fourth-quarter and full-year guidance. Investors should also watch bookings and order trends, software and services margins, AI and drone adoption, federal budget and counter-UAS awards, analyst target revisions, and the path of interest rates given the stock's sensitivity to growth multiples. From what I see, this is important because the upcoming print could shift sentiment quickly.
Integrating AI Signals into My Research
For traders tracking momentum alongside fundamentals, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to analyst research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. I find these signals helpful for surfacing opportunities and monitoring shifts without replacing core fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AXON in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AXON's RSI Indicator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AXON as a result. In 60 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 26 of 39 cases over the following month. The odds of a continued upward trend are 67%.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.356) is normal, around the industry mean (4.932). AXON has a moderately high P/E Ratio (171.324) as compared to the industry average of (16.814). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.060) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement